Dr. Hope S. Rugo explains what KEYNOTE-B49 found about adding Keytruda to chemotherapy for PD-L1-positive, HR-positive, ...
A new trial will test whether a set course of Brukinsa plus sonrotoclax, which target two pathways that drive hairy cell leukemia, can offer an alternative to chemotherapy.
Medicare will move ostomy supplies to six national contracts in 2028. Survivors and clinicians say a poor fit can lead to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results